Compare Adaptive Biotechnologies Corp (ADPT) vs NRG Energy Inc (NRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs NRG Energy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while NRG Energy Inc trades at $137.14 (market cap $29.12B). The key difference: NRG Energy Inc is far larger — about 8.7× Adaptive Biotechnologies Corp's market cap, and NRG Energy Inc pays a 1.38% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NRG | |
|---|---|---|
Market Cap | $3.33B | $29.12B |
Sector | Health | Utilities |
52-Week High | $22.37 | $184.03 |
52-Week Low | $10.24 | $120.65 |
Enterprise Value | $3.19B | $52.95B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NRG Energy trades at $138.01, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $30.71B revenue and $864M net income, though Q1 2026 earnings missed expectations. Valuation metrics show a high P/E ratio of 154.96 but attractive P/S of 0.87. Recent corporate actions include a $0.48 dividend payment in May 2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings, though elevated debt levels and recent earnings miss pose risks. The stock offers value through reasonable sales multiples and dividend income, but investors should monitor execution on 2026 EBITDA guidance of $5.3-5.8B and manage exposure to energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
